medwireNews: Patients with limited-stage small-cell lung cancer (SCLC) that has not progressed after concurrent chemoradiotherapy (CRT) derive a significant survival benefit from the use of consolidation durvalumab, show phase 3 findings.
06-06-2024 | SCLC | Editor's Choice | News